Scarica l'app Stockscreener
2.629
0.34%
0.009
Precedente Chiudi:
$2.62
Aprire:
$2.6073
Volume 24 ore:
11,155
Relative Volume:
0.07
Capitalizzazione di mercato:
$16.18M
Reddito:
-
Utile/perdita netta:
$-33.08M
Rapporto P/E:
-0.8942
EPS:
-2.94
Flusso di cassa netto:
$-25.68M
1 W Prestazione:
+9.09%
1M Prestazione:
-14.08%
6M Prestazione:
+99.17%
1 anno Prestazione:
+44.45%
Intervallo 1D:
$2.5763
$2.65
Intervallo di 1 settimana:
$2.39
$2.65
Portata 52W:
$0.8288
$3.855
Chemomab Therapeutics Ltd Adr Stock (CMMB) Company Profile
Nome
Chemomab Therapeutics Ltd Adr
Settore
Industria
Telefono
972-77-331-0156
Indirizzo
KIRYAT ATIDIM, BUILDING 7, TEL AVIV
Confronta CMMB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CMMB
Chemomab Therapeutics Ltd Adr
|
2.629 | 16.13M | 0 | -33.08M | -25.68M | -2.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.58 | 110.02B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
765.19 | 82.00B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.61 | 59.61B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
890.96 | 56.15B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.44 | 44.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Chemomab Therapeutics Ltd Adr Stock (CMMB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-05-13 | Iniziato | Maxim Group | Buy |
| 2024-05-06 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-12-19 | Ripresa | ROTH MKM | Buy |
Chemomab Therapeutics Ltd Adr Borsa (CMMB) Ultime notizie
Chemomab Therapeutics (NASDAQ:CMMB) Cut to “Hold” at Zacks Research - Defense World
Chemomab reports positive 48-week data for PSC drug nebokitug - Investing.com
ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition - sharewise.com
Best Momentum Stocks to Buy for Oct. 23 - The Globe and Mail
New Strong Buy Stocks for Oct. 23: MQ, GES and More - Yahoo Finance
NVO's Rybelsus Gets FDA Nod to Reduce Heart Risk in Diabetes Patients - sharewise.com
Roche's Gazyva Secures FDA Nod for Label Expansion in Lupus Nephritis - sharewise.com
ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up - The Globe and Mail
Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in Japan - sharewise.com
RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy - sharewise.com
TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals - Zacks Investment Research
Zoetis Gains CVMP Backing for Lenivia, Eyes EU Approval in Dog OA Pain - sharewise.com
TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder - Yahoo Finance
Chemomab Therapeutics (NASDAQ:CMMB) Upgraded by Wall Street Zen to “Hold” Rating - Defense World
CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza - sharewise.com
OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data - sharewise.com
KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure - The Globe and Mail
AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study - Yahoo Finance
Are Smart Investors Making the Right Decision? Chemomab Therapeutics Ltd ADR (CMMB) - Setenews
MRK Expands Tulisokibart Program in Three New Inflammatory Diseases - Zacks Investment Research
Oppenheimer raises Chemomab stock price target to $25 on M&A potential By Investing.com - Investing.com South Africa
Oppenheimer raises Chemomab stock price target to $25 on M&A potential - Investing.com Nigeria
Chemomab Therapeutics price target raised to $25 from $10 at Oppenheimer - TipRanks
CMMB’s Market Whiplash: -34.81% YTD Decline, -15.11% Plunge in 30 Days - investchronicle.com
TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy - sharewise
KURA Stock Rises More Than 15% This Past Week: Here's Why - The Globe and Mail
MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study - sharewise
NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study - Yahoo Finance
CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer - The Globe and Mail
RCKT Stock Tanks On Patient Death In Danon Disease Study - Barchart.com
RCKT Stock Tanks on Patient Death in Danon Disease Study - Yahoo Finance
TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate - Zacks Investment Research
Chemomab prepares for annual shareholder meeting - Investing.com
港股美國預託證券與本港收市比較個別發展 - Yahoo 財經
Chemomab secures $10 million in PIPE financing - Investing.com
Chemomab Therapeutics (CMMB) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Chemomab Therapeutics (CMMB) Stock Trends and Sentiment 2025 - MarketBeat
Chemomab Therapeutics (CMMB) Stock Forecast and Price Target 2025 - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Here's Why Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Chemomab (CMMB) Up on Fast Track Designation to CM-101 for PSC - Yahoo Finance
Chemomab Therapeutics LtdADR (CMMB) News, Articles, Events & Latest Updates - Stocktwits
What is the current Price Target and Forecast for Chemomab Therapeutics (CMMB) - Zacks Investment Research
What date does Chemomab Therapeutics's (CMMB) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
What You Need To Know About Chemomab Therapeutics Ltd.'s (NASDAQ:CMMB) Investor Composition - Yahoo Finance
Chemomab Therapeutics (CMMB) Institutional Ownership 2025 - MarketBeat
Chemomab Therapeutics Ltd Adr Azioni (CMMB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):